Is the Allurion Gastric Balloon Safe? What the Research Shows

Safety is the right question to ask first. Before considering whether a weight loss intervention works, you need to know whether it is safe. This article gives you an honest, evidence-based answer — drawing on published clinical trials, Health Canada guidance, and what over a decade of Allurion programme data shows.

What the Clinical Evidence Shows

The Allurion Gastric Balloon has been used by over 100,000 patients across more than 60 countries since its commercial launch. That is a substantial real-world dataset that goes well beyond early trial conditions.

Published peer-reviewed data — including a 2022 safety and efficacy review in the journal Obesity Surgery — reports a serious adverse event rate of less than 0.3%. For context, this is lower than the serious complication rate associated with many common outpatient procedures.

The balloon is CE-marked in Europe and approved for use in Canada. Ottawa Health Center is a certified Allurion provider, meaning our clinical team has completed the required training and follows the programme protocol set by Allurion’s medical advisory board.

The short version: for appropriately screened patients, the Allurion Gastric Balloon has a well-established safety record that compares favourably to every other medically supervised weight loss intervention available in Ottawa.

What Side Effects to Expect

Understanding the difference between expected side effects and genuine complications is important for anyone considering the programme.

Expected and normal in the first week:

The first three to five days after swallowing the capsule are the adjustment period. Your stomach is accommodating a new object that occupies roughly one-third of its volume. The most common experiences during this period are nausea, vomiting, abdominal cramping, a feeling of pressure or fullness, and acid reflux.

These are not complications — they are a predictable physiological response. Our team at Ottawa Health Center provides anti-nausea and antacid medication at your placement appointment. Most patients manage these symptoms at home. They typically resolve within five to seven days as the stomach adjusts.

Less common but possible:

A small number of patients experience more persistent nausea or reflux beyond the first week. Our team is available by phone throughout the programme. In cases where symptoms are difficult to manage, additional medication can be prescribed.

Rare:

Early spontaneous deflation occurs in approximately 1–2% of cases. When the balloon deflates early, it passes through the digestive system naturally. Your team monitors for signs of early deflation during check-in appointments.

Serious Risks — What the Data Shows

Serious complications with the Allurion are rare. The published serious adverse event rate is below 0.3%, which includes events across a wide range of patients and healthcare settings globally.

The absence of surgical and anaesthetic risk is the most significant safety advantage the Allurion holds over bariatric surgery. Gastric sleeve and bypass surgery carry risks of anaesthetic reaction, surgical site infection, anastomotic leak, and long-term nutritional deficiencies. The 30-day mortality rate for bariatric surgery is approximately 0.1–0.3% in published literature.

The Allurion involves none of these risks. There is no incision, no general anaesthesia, no hospital admission, and no surgical recovery. For patients comparing the Allurion against surgery, this safety difference is often the deciding factor.

Who the Allurion Is Not Suitable For

The Allurion is not appropriate for everyone, and proper screening is essential. Our medical team conducts a full assessment before accepting any patient into the programme.

The Allurion is not suitable for patients who have had prior gastric or oesophageal surgery, those with a hiatal hernia larger than 5cm, patients with severe gastro-oesophageal reflux disease, individuals with inflammatory bowel disease or Crohn’s disease, pregnant women or those planning to become pregnant during the 16 weeks, and people taking anticoagulant medications in certain cases.

This list is not exhaustive. Your full medical history is reviewed during the consultation process. The goal is to ensure the programme is right for your specific situation — not to create unnecessary barriers.

If you are unsure whether you qualify, a free consultation with our medical team is the correct first step. We assess suitability before making any recommendation.

How Safety Compares to Other Weight Loss Options

Versus bariatric surgery: As noted above, the Allurion carries significantly lower risk. Surgery is more effective for very high BMI cases but is not appropriate or desirable for every patient. For those with a BMI between 27 and 40 who want non-surgical weight loss options, the Allurion offers a clinically validated result without surgical risk.

Versus GLP-1 medications: GLP-1 drugs such as Wegovy and Ozempic carry their own side effect profiles — nausea, vomiting, pancreatitis risk, and thyroid concerns flagged in prescribing guidelines. Long-term safety data for newer high-dose GLP-1 drugs is still accumulating. The Allurion’s safety profile is supported by over a decade of data and more than 100,000 patient cases.

Versus doing nothing: It is worth stating plainly that obesity itself carries significant health risk. The WHO classifies obesity as a major risk factor for type 2 diabetes, cardiovascular disease, certain cancers, and premature mortality. For patients with a BMI above 30, the health risks of remaining at current weight typically outweigh the risks of any medically supervised intervention — including the Allurion.

What Medical Supervision Adds to Safety

The Allurion is not a device you purchase and use independently. Every programme at Ottawa Health Center is medically supervised from the pre-placement assessment through to the post-balloon maintenance phase.

Supervision matters for safety because it means any unusual response is identified early, medication management is provided throughout the first week, check-in appointments catch signs of early deflation or complications, and the post-balloon period is supported to protect results and overall health.

Medically supervised weight loss is not just about results — it is the structure that makes the programme safe and sustainable.

Taking the Next Step

If you have safety concerns about the Allurion Gastric Balloon, a free consultation with our medical team is the right place to address them. We will review your health history, explain exactly what to expect, and answer every question you have before you make any decision.

Book your free consultation →